DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer
This study is testing whether adding a medication called darolutamide to standard hormone therapy and radiation can help prevent very high-risk prostate cancer from returning. Researchers want to see if this combination works better than standard therapy alone.
This study is no longer taking new participants and has already enrolled the men it needs. It was designed for adult men with very high-risk localized prostate cancer who were scheduled to receive radiation therapy.
Each participant's group is chosen at random by chance, not by you or your doctor. You may receive either the study medicine darolutamide or a placebo, which is an inactive look-alike pill, alongside your usual hormone therapy and radiation.
The study takes place across 93 sites in 6 countries, including Australia, Canada, the United States, the United Kingdom, Ireland, and New Zealand. This study is currently active but not recruiting new participants.
- 1Testing if darolutamide improves standard prostate cancer treatment
- 2Study groups are chosen by chance
- 3The study is active but not taking new participants
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.